Endocrinology & Diabetes

Endocrine and Diabetes Biomarkers

A biomarker is defined as any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease. For the purpose of predicting type 1 diabetes, a biomarker should be present in a subset of the population, and this subset should have a bias in the proportion of people in whom type 1 diabetes develops. A biomarker should also present a quantifiable risk for the development of type 1 diabetes within a defined period or diagnose a “stage” in the progression to clinical or symptomatic type 1 diabetes. As described in this article, most of the biomarkers used for the prediction of type 1 diabetes are islet-specific supporting the concept that, before overt hyperglycemia, type 1 diabetes is predominantly a targeted disease rather than a systemic disease.

Atomic Biomarkers can be separated as "a trademark that is precisely measured and gaged as a pointer of typical natural methods, pathogenic methodology, or pharmacologic reactions to a pharmaceutical intercession.

Biomarkers have fundamental influence in driving clinical trials and treating patients. Progresses in sub-atomic diagnostics help medicinal experts make proficient, experimentally legitimate choices. All the more efficient disclosure and use of biomarkers in the development of ant diabetes medications will rely on upon quickening our comprehension of the pathogenesis of diabetes and particularly its macro vascular entanglements. Procedural upgrades from different fields, particularly tumor, are starting to demonstrate the way towards better models of diabetes pathogenesis and atomic biomarker revelation.

• Prognostic marker
• Diabetic nephropathy marker
• Molecular marker for metabolic syndrome
• Molecular Marker-Hypoglycemic response
• Inflammatory markers: Type 2 diabetes
• Pharmacotherapy in treatment of diabetes